*ST赛隆：继续公开挂牌转让全资子公司赛隆生物股权

Group 1 - The company announced the decision to transfer 100% equity of its wholly-owned subsidiary, Hunan Sailong Biopharmaceutical Co., Ltd., through public listing to optimize resource allocation and improve operational efficiency [1] - The initial public listing price for the subsidiary was set at RMB 86.95 million, based on an assessment by Beijing Kunyuan Zhicheng Asset Appraisal Co., Ltd. [1] - The first public listing period ended without attracting any qualified buyers, prompting the company to reduce the listing price by 10% to RMB 78.255 million for a second attempt [2] Group 2 - The company plans to continue the public listing process, with the possibility of further price reductions if no qualified buyers are found in subsequent rounds [2] - The board of directors has proposed to authorize management to handle all matters related to the equity transfer, including listing, signing agreements, and transferring ownership [2] - The transfer of the subsidiary's equity does not constitute a major asset restructuring according to relevant regulations, and if successful, the subsidiary will no longer be included in the company's consolidated financial statements [2]